AUTL Autolus Therapeutics plc
Price Chart
Executive Summary
Autolus Therapeutics released a post-hoc analysis of the Phase Ib/II FELIX study for ASCO, showing obe-cel achieved a 59% overall response rate and 42.6-month median duration of response in r/r B-ALL patients with extramedullary disease. The abstract is a scientific presentation, not a regulatory event, but provides incremental clinical validation for a difficult-to-treat subpopulation.
Actionable Insight
This is a clinically supportive but non-catalytic data release. Watch for the full ASCO presentation on May 30 for potential incremental commercial sentiment. No pricing, revenue, or guidance change — near-term catalyst is the ASCO session.
Key Facts
- Post-hoc analysis of Phase Ib/II FELIX study (NCT04404660) evaluating obe-cel in r/r B-ALL patients with extramedullary disease (EMD).
- 27 of 127 infused patients (21%) had EMD at lymphodepletion.
- Overall response rate 59% and median duration of response 42.6 months in EMD patients.
- Abstract to be presented at ASCO Annual Meeting (May 29 – June 2, 2026) as Rapid Oral Abstract.
- Obe-cel is already a marketed therapy (AUCATZYL), so this is supportive data rather than a new approval event.
Financial Impact
No financial figures disclosed. The data supports obe-cel's clinical profile in EMD patients, which may modestly support commercial adoption but does not change near-term revenue guidance.
Risk Factors
- Post-hoc analysis carries lower evidence weight than prospective studies; no guarantee of label expansion.
- Competing CAR-T therapies (e.g., tisagenlecleucel, brexucabtagene autoleucel) already address B-ALL.
- Autolus has a $431M market cap and is pre-revenue at scale; commercial adoption of AUCATZYL is early-stage.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299801 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
8-K
| $1.45 awaiting T+5 | awaiting T+5 | — | $1.46 (−0.69%) |
|
May 21, 2026
19d ago
|
Press Release
| $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.46 (−14.12%) |
|
May 14, 2026
26d ago
|
8-K
| $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.46 (−8.18%) |
|
May 14, 2026
26d ago
|
Press Release
| $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.46 (−8.18%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $1.60 $1.42 | ▼ −11.56% | ▼ −11.62% | $1.46 (−8.75%) |
|
Apr 8, 2026
8w ago
|
8-K
| $1.47 $1.61 | ▲ +9.52% | ▲ +6.34% | $1.46 (−0.68%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $1.51 $1.32 | ▼ −12.58% | ▼ −9.93% | $1.46 (−3.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access